|
|
|
Volumn 26, Issue 4 SUPPL. 12, 1999, Pages 71-77
|
|
Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTHRACYCLINE ANTIBIOTIC AGENT;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
EPIRUBICIN;
MONOCLONAL ANTIBODY;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
ARTICLE;
BREAST CANCER;
BREAST METASTASIS;
CANCER COMBINATION CHEMOTHERAPY;
CLINICAL TRIAL;
DRUG EFFECT;
DRUG EFFICACY;
DRUG SAFETY;
GROWTH INHIBITION;
HUMAN;
ONCOGENE NEU;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROTEIN DOMAIN;
PROTEIN EXPRESSION;
TARGET CELL;
TUMOR GROWTH;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
CLINICAL TRIALS;
FEMALE;
HUMANS;
NEOPLASM METASTASIS;
RECEPTOR, ERBB-2;
|
|
EID: 0032844121
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (283)
|
|
References (21)
|
